MADRID, 8 Abr. (EUROPA PRESS) -

EthiFinance Ratings, a European credit rating agency, has announced that it maintains PharmaMar's long-term credit ratings at 'BB' with a stable trend, as reported this month by the company at the Comisión Nacional del Mercado de Valores (CNMV).

For its part, the executive committee of PharmaMar, empowered by the board of directors, decided last Thursday to execute the plan to distribute treasury shares, for which it will distribute among its employees and directors up to a total of 18,510 shares, equivalent to 0.1008% of the company's share capital.

Specifically, the total amount of these actions is 524,973.22 euros and in no case may the amount of 12,000 euros per beneficiary be exceeded.

The firm closed 2023 with a net profit of 1.14 million euros, which represents a decrease of almost 98% compared to the previous year, when it earned 49.36 million euros.